Update on the safety of thiazolidinediones

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 116-123

  Lieb, David C ^a   McCall, Anthony L ^b  

^a Ctr for Endocr and Metab Disord   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cardiovascular disease; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; FRACTURE; GLYCEMIC CONTROL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); RISK FACTOR;

CLINICAL TRIALS AS TOPIC; FRACTURES, BONE; HEART FAILURE; HUMANS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 77953610924     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0099-1     Document Type: Review

References (45)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Preis SR, Pencina MJ, Hwang S, et al.: Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220.
3. Fox CS, Coady S, Sorlie PD, et al.: Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544-1550.
4. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001, 111:633-642.
5. Kelly TN, Bazzano LA, Fonseca VA, et al.: Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
6. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545-2559.
7. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
8. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560-2572.
9. Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
10. Gleissner CA, Galkina E, Nadler JL, Ley K: Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007, 4:131-140.
11. Lebovitz HE: Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002, 90:34G-41G.
12. Agarwal R: Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006, 290:F600-F605.
13. Katavetin P, Eiam-Ong S, Suwanwalaikorn S: Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai 2006, 89:170-177.
14. Tolman KG, Chandramouli J: Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003, 7:369-379, vi.
15. Patel RR: Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Cardiol Rev 2009, 17:132-135.
16. Dormuth CR, Carney G, Carleton B, et al.: Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395-1402.
17. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
18. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
19. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007, 357:28-38.
20. Mannucci E, Monami M: Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? Curr Diab Rep 2009, 9:342-347.
21. Mannucci E, Monami M, Di Bari M, et al.: Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009 Mar 26 [Epub ahead of print].
22. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
23. Erdmann E, Dormandy JA, Charbonnel B, et al.: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772-1780.
24. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
25. Mannucci E, Monami M, Lamanna C, et al.: Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008, 10:1221-1238.
26. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
27. McCall AL: When is evidence of lack of harm enough? Has the rosiglitazone controversy ended? Curr Diab Rep 2009, 9:325-328.
28. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. N Engl J Med 1996, 335:217-225.
29. Frye RL, August P, Brooks MM, et al.: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515.
30. Chaitman BR, Hardison RM, Adler D, et al.: The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529-2540.
31. Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
32. Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006, 17:3482-3490.
33. Ali AA, Weinstein RS, Stewart SA, et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
34. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al.: Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulinlike growth factor regulatory system in vitro and in vivo. Endocrinology 2007, 148:903-911.
35. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
36. Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820-825.
37. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349-3354.
38. Aronoff S, Rosenblatt S, Braithwaite S, et al.: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23:1605-1611.
39. Lebovitz HE, Dole JF, Patwardhan R, et al.: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
40. Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
41. Starner CI, Schafer JA, Heaton AH, Gleason PP: Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008, 14:523-531.
42. Fisman EZ, Tenenbaum A: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovascular Diabetology 2009, 8:38.
43. Duncker DJ, Van Zon NS, Altman JD, et al.: Role of K+ATP channels in coronary vasodilation during exercise. Circulation 1993, 88:1245-1253.
44. Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33:119-124.
45. Tzoulaki I, Molokhia M, Curcin V, et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009, 339b:4731.